Search

Your search keyword '"Ohtsuka, Takashi"' showing total 687 results
Start Over Author "Ohtsuka, Takashi"
687 results on '"Ohtsuka, Takashi"'

6. Mitigation of acute lung injury by human bronchial epithelial cell-derived extracellular vesicles via ANXA1-mediated FPR signaling.

Author

Fujita, Yu, Kadota, Tsukasa, Kaneko, Reika, Hirano, Yuta, Fujimoto, Shota, Watanabe, Naoaki, Kizawa, Ryusuke, Ohtsuka, Takashi, Kuwano, Kazuyoshi, Ochiya, Takahiro, and Araya, Jun

Subjects
Acute Lung Injury, Humans, Extracellular Vesicles, Annexin A1, Animals, Signal Transduction, Mice, Receptors, Formyl Peptide, Epithelial Cells, Bronchi, Male, Mice, Inbred C57BL, MicroRNAs, NF-kappa B, Cytokines, THP-1 Cells, Receptors, Lipoxin
Abstract

Acute lung injury (ALI) is characterized by respiratory failure resulting from the disruption of the epithelial and endothelial barriers as well as immune system. In this study, we evaluated the therapeutic potential of airway epithelial cell-derived extracellular vesicles (EVs) in maintaining lung homeostasis. We isolated human bronchial epithelial cell-derived EVs (HBEC-EVs), which endogenously express various immune-related surface markers and investigated their immunomodulatory potential in ALI. In ALI cellular models, HBEC-EVs demonstrated immunosuppressive effects by reducing the secretion of proinflammatory cytokines in both THP-1 macrophages and HBECs. Mechanistically, these effects were partially ascribed to nine of the top 10 miRNAs enriched in HBEC-EVs, governing toll-like receptor-NF-κB signaling pathways. Proteomic analysis revealed the presence of proteins in HBEC-EVs involved in WNT and NF-κB signaling pathways, pivotal in inflammation regulation. ANXA1, a constituent of HBEC-EVs, interacts with formyl peptide receptor (FPR)2, eliciting anti-inflammatory responses by suppressing NF-κB signaling in inflamed epithelium, including type II alveolar epithelial cells. In a mouse model of ALI, intratracheal administration of HBEC-EVs reduced lung injury, inflammatory cell infiltration, and cytokine levels. Collectively, these findings suggest the therapeutic potential of HBEC-EVs, through their miRNAs and ANXA1 cargo, in mitigating lung injury and inflammation in ALI patients.

Published
2024

11. Benefit of Adjuvant Chemotherapy for Patients Older Than 75 Years With Completely Resected p-Stage II-IIIA Non–Small-Cell Lung Cancer: A Retrospective Cohort Study Using Japanese Nationwide Real-World Data

Author

Adachi, Hiroyuki, Morohoshi, Takao, Shintani, Yasushi, Okami, Jiro, Ito, Hiroyuki, Ohtsuka, Takashi, Mori, Takeshi, Watanabe, Shun-ichi, Chida, Masayuki, Endo, Shunsuke, Nakanishi, Ryoichi, Kadokura, Mitsutaka, Suzuki, Hidemi, Miyaoka, Etsuo, Yoshino, Ichiro, and Date, Hiroshi

Published
2024
Full Text
View/download PDF

16. Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative study.

Author

Hara, Shuhei, Urabe, Fumihiko, Tashiro, Kojiro, Goto, Yuma, Iwamoto, Yuya, Ohtsuka, Takashi, Fukuokaya, Wataru, Imai, Yu, Iwatani, Kosuke, Atsuta, Mahito, Mori, Keiichiro, Igarashi, Taro, Aikawa, Koichi, Yanagisawa, Takafumi, Kimura, Shoji, Murakami, Masaya, Tsuzuki, Shunsuke, Yanada, Brendan A, Hata, Kenichi, and Furuta, Akira

Published
2025
Full Text
View/download PDF

19. Survival after Lung Metastasectomy from Urothelial Carcinoma: A Multi-Institutional Database Study.

Author

Yamauchi, Yoshikane, Sato, Masaaki, Iwata, Takekazu, Endo, Makoto, Ikeda, Norihiko, Hashimoto, Hiroshi, Hato, Tai, Suzuki, Hidemi, Matsuguma, Haruhisa, Shintani, Yasushi, Kondo, Haruhiko, Oyama, Takahiko, Azuma, Yoko, Iida, Tomohiko, Sakakura, Noriaki, Mun, Mingyon, Asakura, Keisuke, Ohtsuka, Takashi, Uehara, Hirofumi, and Sakao, Yukinori

Subjects
BLADDER tumors, KIDNEY tumors, PELVIC tumors, COMPUTED tomography, TREATMENT effectiveness, MULTIVARIATE analysis, DESCRIPTIVE statistics, METASTASECTOMY, TRANSITIONAL cell carcinoma, METASTASIS, MULTIHOSPITAL systems, LONGITUDINAL method, LUNG tumors, CONFIDENCE intervals, PROGRESSION-free survival, OVERALL survival, EVALUATION
Abstract

Simple Summary: This study examined the outcomes of lung metastasectomy in urothelial carcinoma patients using data from a Japanese multi-institutional database. The study included 100 patients who underwent the procedure between 1985 and 2021. Results showed 5-year overall survival and disease-free survival rates of 59% and 46%, respectively. Larger tumor diameter and presence of distant metastases at primary cancer treatment were identified as significant adverse prognostic factors. The authors claim that this is the largest published case series on this topic, providing benchmark data for assessing long-term outcomes. Background/objectives: The efficacy of lung metastasectomy in patients with urothelial carcinoma remains inconclusive, as there is only limited evidence from small studies. In this study, we aimed to assess the prognostic outcomes of excising pulmonary metastases from urothelial carcinoma. Methods: In this study, we utilized data from the Metastatic Lung Tumor Study Group of Japan database, a multi-institutional prospective database of pulmonary metastasectomies. We examined the data of patients who had undergone pulmonary metastasectomy for urothelial carcinoma between 1985 and 2021. Exclusion criteria included insufficient clinical information and follow-up of <3 months. Results: The study cohort comprised 100 patients (63 bladder cancer, 37 renal pelvic and ureteral cancer), with a median follow-up of 34 months. There were 70 male and 30 female patients of average age 66.5 ± 10.4 years at lung metastasectomy. The median interval from treatment of the primary lesion to metastasectomy was 19 months and the maximum tumor diameter was 21 ± 15 mm. Three- and five-year overall survival rates were 69% and 59%, respectively. Three- and five-year disease-free survival rates were 56% and 46%, respectively. Multivariate analysis identified larger tumor diameter (hazard ratio: 1.62, 95% confidence interval: 1.21–2.17) and distant metastases at the time of treatment of the primary cancer (hazard ratio: 4.23; 95% confidence interval: 1.54–11.6) as significant adverse prognostic factors for overall survival. Conclusions: To our knowledge, this is the largest published case series of pulmonary resection for metastatic urothelial carcinoma, providing benchmark data for the assessment of long-term outcomes of this rare entity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small cell lung cancer: A retrospective analysis of 16,503 cases in a Japanese Lung Cancer Registry Study

Author

Fukumoto, Koichi, Mori, Shoichi, Shintani, Yasushi, Okami, Jiro, Ito, Hiroyuki, Ohtsuka, Takashi, Toyooka, Shinichi, Mori, Takeshi, Watanabe, Shun-ichi, Asamura, Hisao, Chida, Masayuki, Date, Hiroshi, Endo, Shunsuke, Nagayasu, Takeshi, Nakanishi, Ryoichi, Miyaoka, Etsuo, Okumura, Meinoshin, and Yoshino, Ichiro

Published
2020
Full Text
View/download PDF

29. Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18,973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010

Author

Okami, Jiro, Shintani, Yasushi, Okumura, Meinoshin, Ito, Hiroyuki, Ohtsuka, Takashi, Toyooka, Shinichi, Mori, Takeshi, Watanabe, Shun-ichi, Date, Hiroshi, Yokoi, Kohei, Asamura, Hisao, Nagayasu, Takeshi, Miyaoka, Etsuo, and Yoshino, Ichiro

Published
2019
Full Text
View/download PDF

30. Optimal sublobar resection for c-stage I non-small cell lung cancer: significance of margin distance to tumor size ratio and margin cytology (Supplementary analysis of KLSG-0801): complete republication

Author

Takahashi, Nobumasa, Sawabata, Noriyoshi, Kawamura, Masafumi, Ohtsuka, Takashi, Horio, Hirotoshi, Sakaguchi, Hirozo, Nakayama, Mitsuo, Yoshiya, Katsuo, Chida, Masayuki, Hoshi, Eishin, and All the co-authors are members of Kan-Etsu Lung Cancer Study Group (KLSG)

Published
2019
Full Text
View/download PDF

33. Benefit of adjuvant chemotherapy for patients older than 75 years with completely resected p-stage II–IIIA non-small cell lung cancer: A retrospective cohort study using Japanese nationwide real-world data

Author

Adachi, Hiroyuki, primary, Morohoshi, Takao, additional, Shintani, Yasushi, additional, Okami, Jiro, additional, Ito, Hiroyuki, additional, Ohtsuka, Takashi, additional, Mori, Takeshi, additional, Watanabe, Shun-ichi, additional, Chida, Masayuki, additional, Endo, Shunsuke, additional, Nakanishi, Ryoichi, additional, Kadokura, Mitsutaka, additional, Suzuki, Hidemi, additional, Miyaoka, Etsuo, additional, Yoshino, Ichiro, additional, and Date, Hiroshi, additional

Published
2023
Full Text
View/download PDF

34. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma

Author

Kinoshita, Tomonari, Kudo-Saito, Chie, Muramatsu, Reiko, Fujita, Tomonobu, Saito, Miyuki, Nagumo, Haruna, Sakurai, Toshiharu, Noji, Shinobu, Takahata, Emi, Yaguchi, Tomonori, Tsukamoto, Nobuo, Hayashi, Yuichiro, Kaseda, Kaoru, Kamiyama, Ikuo, Ohtsuka, Takashi, Tomizawa, Kenji, Shimoji, Masaki, Mitsudomi, Tetsuya, Asamura, Hisao, and Kawakami, Yutaka

Published
2017
Full Text
View/download PDF

44. Weight loss of 5% or more after lobectomy for lung cancer via minimally invasive approaches is associated with poor prognosis.

Author

Nakada, Takeo, Nakashima, Maki, Tsukamoto, Yo, Kato, Daiki, Shibazaki, Takamasa, and Ohtsuka, Takashi

Subjects
WEIGHT loss, LOBECTOMY (Lung surgery), LUNG cancer, NON-small-cell lung carcinoma, CANCER prognosis, BODY mass index
Abstract

Introduction: We analyzed the association between postoperative weight loss (WL), preoperative body mass index (BMI), and prognosis in patients with lung cancer who underwent lobectomy using minimally invasive approaches. Methods: Weight change in 325 patients who underwent radical lobectomy for non‐small cell lung cancer was assessed at 3, 6, and 12 months postoperatively and compared to preoperative weight. Patients were divided into three groups according to their preoperative BMI interquartile range: low BMI ≤20.3 kg/m2, middle BMI 20.4–24.4 kg/m2, and high BMI ≥24.5 kg/m2. Postoperative WL ≥5% was evaluated with reference to frailty. Results: There were no significant differences in pathological findings, postoperative complications, or postoperative hospital stay among the three groups. Thirty all‐cause deaths and 39 cancer recurrences occurred. Within the first year after surgery, WL of any grade was observed in 229 patients (70.5%) and WL ≥5% in 86 patients (26.5%). Postoperative WL of any grade within 1 year after surgery was not associated with OS and RFS (both p >.05). However, WL ≥5% within 1 year after surgery was associated with worse OS and RFS (p =.007 and.006, respectively). WL ≥5% within 1 year after surgery was more common in the low BMI group (p =.045). There was no difference in OS and RFS among the BMI groups in patients with WL ≥5% and those without WL ≥5% (all p >.05). Conclusion: WL ≥5% was associated with poor prognosis after lobectomy via minimally invasive approaches. Weighing is a useful prognostic marker that can be easily self‐checked. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results